舍曲林联合普瑞巴林治疗胸背部带状疱疹后神经痛的临床疗效分析

蔡薇; 丁娟; 龚敏操

doi:10.16766/j.cnki.issn.1674-4152.000110

舍曲林联合普瑞巴林治疗胸背部带状疱疹后神经痛的临床疗效分析

doi: 10.16766/j.cnki.issn.1674-4152.000110

蔡薇^1, ,,
丁娟¹,
龚敏操²

1. 绍兴市人民医院皮肤科, 浙江绍兴 312000;
2. 浙江省中医院麻醉科, 浙江杭州 310006

基金项目:

浙江省中医药科学研究基金计划(2013ZA038)

详细信息

通讯作者:
蔡薇,E-mail:xsf0224@163.com

中图分类号: R752.12
计量
- 文章访问数: 444
- HTML全文浏览量: 89
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2017-01-15
- 网络出版日期: 2022-07-22

Clinical efficacy of sertraline combined with pregabalin in the treatment of thoracic back postherpetic neuralgia

Dermatology Department, Shaoxing People's Hospital, Shaoxing, Zhejiang 312000, China

摘要

摘要: 目的探讨舍曲林联合普瑞巴林治疗胸背部带状疱疹后神经痛的临床疗效。方法将2015年3月-2016年3月绍兴市人民医院收治的96例胸背部带状疱疹后神经痛患者按照随机数字表法分为对照组和研究组,每组48例。对照组在常规对症治疗基础上行口服普瑞巴林治疗;研究组在对照组治疗的基础上行口服盐酸舍曲林治疗。于治疗前、治疗后2周、1个月、2个月、3个月,采用视觉模拟评分法(VAS)评价患者疼痛程度,采用生活量表(QOL)评价患者生存质量变化;观察并记录2组治疗过程中药物相关不良反应的发生情况。结果研究组疗效显著高于对照组,差异有统计学意义(Z=2.288,P<0.05)。治疗后2周、1个月、2个月、3个月,2组VAS评分显著降低(均P<0.05);治疗后2周、1个月、2个月、3个月,研究组VAS评分显著低于对照组,差异有统计学意义(均P<0.05)。2组治疗后QOL评分均较治疗前显著降低(P<0.05);治疗后2周、1个月、2个月、3个月,研究组在食欲、睡眠、情绪、精神状态的评分均显著低于对照组同期的水平,差异有统计学意义(均P<0.05)。研究组药物相关不良反应发生率(16.67%)与对照组(12.50%)相比,差异无统计学意义(P>0.05)。结论舍曲林联合普瑞巴林能显著改善胸背部带状疱疹后神经痛患者临床症状,提高治疗有效率,改善疼痛程度和生活质量。
- 舍曲林 /
- 普瑞巴林 /
- 带状疱疹 /
- 神经痛
Abstract: Objective To investigate the clinical efficacy of sertraline combined with pregabalin in the treatment of thoracic back postherpetic neuralgia. Methods Total 96 patients with postherpetic neuralgia of chest and back were divided into control group and research group according to random number table method, with 48 cases in each group. The control group received oral pregabalin based on the conventional treatment. The research group received additional sertraline. The patients were evaluated by visual analogue scale(VAS) before the treatment, 2 weeks, 1 months, 2 months and 3 months after the treatment. Life quality scale(QOL) was used to evaluate the quality of life of patients. The incidence of adverse drug reactions in the two groups were observed and recorded. Results The curative effect of the research group was significantly higher than that of the control group, the difference was statistically significant(Z=2.288, P<0.05). After 2 weeks, at the end of the 1 month, the 2 month and the 3 month, the VAS scores of the two groups were significantly decreased (P<0.05). After treatment for 2 weeks, 1 month, 2 months, and 3 months, the VAS score of the study group was significantly lower than that of the control group, the difference was statistically significant(P<0.05). The QOL scores of the two groups after the treatment were significantly lower than those before the treatment(P<0.05). After 2 weeks, 1 months, 2 months, and 3 months after treatment, the scores of appetite, sleep, mood and mental state of the study group were significantly lower than those of the control group, the difference was statistically significant(P<0.05). The incidence of adverse drug reactions(16.66%) in the study group was significantly higher than that in the control group(12.50%), there was no significant difference(P>0.05). Conclusion Sertraline combined with pregabalin can significantly improve the clinical symptoms of patients with postherpetic neuralgia of chest and back, improve the treatment efficiency, improve the degree of pain and quality of life.
- Sertraline /
- Pregabalin /
- Herpes zoster /
- Neuralgia